Table 1. Clinical Characteristic of the Patients (Cited and Modified from Tjan LH, Nagano T, Furukawa K, et al. The trend of neutralizing antibody response against SARS-CoV-2 and the cytokine/chemokine release in patients with differing severities of COVID-19: all individuals infected with SARS-CoV-2 obtained neutralizing antibody. medRxiv. 2020 (19). Copyright of the Table Belongs to the Authors).

From: The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients

Code Sex, Age Severitya Medical historyb Hospitalization duration Upper respiratory symptomc Pneumonia Persistent imaging abnormalities Ventilator introduction (dpod) Ventilator removal (dpod) Treatmente Equipmentf Outcome
K-Px-10 M, 59 Asymptomatic DM, glaucoma 20 n.d. n.d. Alive
K-Px-13 M, 54 Asymptomatic 8 n.d. n.d. Alive
K-Px-14 F, 54 Asymptomatic DM 8 n.d. n.d. Alive
K-Px-15 M, 19 Asymptomatic 9 n.d. n.d. Alive
K-Px-16 M, 19 Asymptomatic 2 n.d. n.d. Alive
K-Px-12 M, 71 Severe AR, BA, BPH 35 + + + C Alive
K-Px-1 F, 59 Severe Cervical cancer, HL, HT, SAS 23 + + + C, F Alive
K-Px-9 F, 69 Severe HL, HT 21 + + + C, F Alive
K-Px-2 M, 57 Critical 56 + + + 8 33 F, L/R CHDF, HD Alive
K-Px-3 M, 74 Critical DM, glaucoma, HL 44 + + + 11 50 C, F, L/R CHDF Dead (51 dpod)
K-Px-4 F, 63 Critical Osteoporosis 80 + + + 16 65 C, F, L/R ECMO Alive
K-Px-5 M, 65 Critical HT, hyperuricemia 93 + + 12 32 C, F, L/R CHDF Alive
K-Px-6 M, 79 Critical Arrhythmia, CI, dementia 16 + + + 6 15 C, F, L/R Dead (16 dpod)
K-Px-7 M, 78 Critical AAA, AP, arrhythmia, ASO, CHF, CKD, DM, GB, HT 17 + + + 8 21 C, F Dead (22 dpod)
K-Px-8 F, 79 Critical DM, IgA nephropathy 73 + + + 0 36 F, L/R, Steroid (6-9 dpod) CRRT Alive
PAGE TOP